Germany DNA Vaccine Market to Reach USD 94.55 Million by 2035

Germany DNA Vaccine Market was valued at $60.73 million in 2025 and is projected to reach $94.55 million by 2035, growing at a CAGR of 4.6% during the forecast period (2026–2035). The market is gaining traction as key manufacturers expand their GMP-grade plasmid DNA production capacity, which underpins DNA vaccine construct development and clinical supply. Domestic production infrastructure now includes newly inaugurated or expanded facilities capable of supporting both clinical-scale and commercial plasmid DNA output, enhancing production autonomy and supply reliability within the country. Strategic collaborations to refine plasmid manufacturing workflows are also underway, reflecting industry efforts to improve scalability and technological efficiency. These developments are helping reduce dependence on external supply chains and align production with German regulatory requirements, strengthening the overall market ecosystem. The cumulative effect is a more resilient, efficient, and strategically positioned platform for advancing DNA vaccine programs across therapeutic applications.

Browse the full report description of “Germany DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/germany-dna-vaccines-market

• BioNTech SE completed its first proprietary plasmid DNA manufacturing facility in Marburg, Germany, as part of its manufacturing expansion, enabling local production of plasmid DNA for clinical and commercial use in oncology and infectious disease vaccine programs.

• The clinical-scale plant at BioNTech’s Marburg site has been operational since August 2022, with plans to scale commercial production pending regulatory approval, increasing production flexibility, and shortening delivery timelines.

• Richter BioLogics GmbH & Co KG inaugurated a new multi-purpose cGMP biopharmaceutical facility in Bovenau, Germany, equipped for clinical and large-scale plasmid DNA manufacturing alongside protein production.

• The Richter BioLogics facility includes new 300L and 1500L production lines enabling simultaneous manufacture of multiple products and up to 120 batches per year, significantly enhancing local capacity.

• WACKER Chemie AG announced a strategic collaboration with Gearbox Biosciences to advance plasmid DNA manufacturing technologies that improve scalability, quality, and sustainability, reinforcing Germany’s role in innovative pDNA production.

These developments build on ongoing capital investment and facility upgrades in Germany, positioning local manufacturers to better support DNA vaccine supply chains and clinical pipelines within the broader European market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Technology
  • Application
• Competitive Landscape – Aldevron, AGC Biologics, BioNTech SE, Inovio Pharmaceuticals, Inc., PlasmidFactory GmbH, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Germany DNA Vaccine Market Report Segment

By Type

• Animal DNA Vaccine
• Human DNA Vaccine

By Technology

• Plasmid DNA Vaccines Technology
• Plasmid DNA Delivery Technology

By Application

• Oncology
• Infectious Diseases
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-dna-vaccines-market